Table 1.
Physical examinations in children hospitalized with diarrhea at admission and after four days of treatment with the allotted phage or placebo product.
| Treatment |
T4-phage |
Microgen phage |
Placebo |
|||
|---|---|---|---|---|---|---|
| Time |
Adm |
Day 4 |
Adm |
Day 4 |
Adm |
Day 4 |
| n | 25 | 23 | 26 | 20 | 27 | 23 |
| Age, month | 10 ± 3.2 (8.8–11.3) | 12 ± 4.1 (10.4–13.6) | 13 ± 4.8 (11.2–14.8) | |||
| Weight, kg | 8.1 ± 1.3 (7.6–8.6) | 8.0 ± 1.3 (7.5–8.5) | 8.4 ± 1.4 (7.9–8.9) | 8.3 ± 1.5 (7.6–9.0) | 8.4 ± 1.5 (7.8–9.0) | 8.2 ± 1.7 (7.5–8.9) |
| Temp, °C | 36.9 ± 0.5 (36.7–37.1) | 36.7 ± 0.5 (36.5–36.9) | 36.7 ± 0.6 (36.5–36.7) | 36.5 ± 0.4 (36.3–36.7) | 36.9 ± 0.8 (36.6–37.2) | 36.8 ± 0.7 (36.5–37.1) |
| Pulse/min | 119 ± 7 (116–122) | 118 ± 4 (116–120) | 121 ± 5 (119–123) | 118 ± 5 (116–120) | 120 ± 6 (118–122) | 119 ± 5 (117–121) |
| Respiration/min | 33 ± 6 (31–35) | 31 ± 2 (30–32) | 32 ± 5 (30–34) | 30 ± 3 (29–31) | 34 ± 3 (33–35) | 32 ± 2 (31–33) |
| BP systolic (mmHg) | 89 ± 6 (87–91) | 86 ± 5 (84–88) | 89 ± 6 (87–91) | 87 ± 5 (85–89) | 88 ± 5 (86–90) | 87 ± 5 (85–89) |
| BP diastolic | 54 ± 5 (52–56) | 53 ± 4 (51–55) | 56 ± 6 (54–58) | 52 ± 3 (51–53) | 57 ± 8 (54–60) | 55 ± 4 (53–57) |
n, number of children per investigated group. Values are means ± standard deviations (95% CI).
No significant differences were seen between clinical parameters at admission and 4 days of phage or placebo treatment in diarrhea patients in paired t-tests. However, T4-phage treated children were significantly younger than placebo recipients (P = 0.01 in t-test), but did not differ from Microgen phage treated children.